Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab
Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3174-3175
DOI: 10.1200/jco-26-00565 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Qinglin Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Qinglin Li, MD, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province), Hangzh…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Qinglin Li, MD, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province), Hangzhou, China; Zulei Shao, MM, Postgraduate Training Base Alliance, Wenzho…
ORCID-Profile: Xiaoling Xu
Zitieren
APA
Li, Q., Shao, Z., Xu, X., & Mao, W. (2026). Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab. Journal of Clinical Oncology, 44(32), 3174-3175. https://doi.org/10.1200/jco-26-00565
Vancouver
Li Q, Shao Z, Xu X, Mao W. Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab. Journal of Clinical Oncology. 2026;44(32):3174-3175. doi:10.1200/jco-26-00565
BibTeX
@article{Li2026,
author = {Li, Qinglin and Shao, Zulei and Xu, Xiaoling and Mao, Weimin},
title = {Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {32},
pages = {3174--3175},
doi = {10.1200/jco-26-00565}
}
EUVIMED